Vista Investment Partners LLC Raises Stock Position in Pfizer Inc. $PFE

Vista Investment Partners LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 236.1% in the 3rd quarter, HoldingsChannel reports. The fund owned 69,613 shares of the biopharmaceutical company’s stock after acquiring an additional 48,900 shares during the period. Vista Investment Partners LLC’s holdings in Pfizer were worth $1,774,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Fiduciary Alliance LLC raised its holdings in shares of Pfizer by 46.4% in the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock worth $3,701,000 after buying an additional 46,043 shares during the last quarter. Westbourne Investments Inc. purchased a new stake in shares of Pfizer during the first quarter valued at $2,411,000. Bourne Lent Asset Management Inc. increased its position in shares of Pfizer by 90.8% in the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after acquiring an additional 18,200 shares during the period. Ossiam raised its stake in Pfizer by 71.2% in the 2nd quarter. Ossiam now owns 5,650,573 shares of the biopharmaceutical company’s stock worth $136,970,000 after acquiring an additional 2,349,058 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. raised its stake in Pfizer by 76.4% in the 3rd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock worth $2,784,000 after acquiring an additional 47,319 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 0.7%

Pfizer stock opened at $25.05 on Friday. The business’s 50-day moving average price is $25.15 and its 200 day moving average price is $24.88. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The firm has a market cap of $142.40 billion, a price-to-earnings ratio of 14.56 and a beta of 0.46. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. The business had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PFE. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. Finally, UBS Group restated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $28.06.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.